tirzepatide judge US denies injunction, restricting copies of Lilly weight-loss drug Tirzepatide equally effective for early-onset
Description
In the SURPASS-2 head-to-head clinical trial, all three Tirzepatide doses demonstrated statistically superior HbA1c reduction and weight reduction compared to Semaglutide 1mg over 40 weeks

For a wider three-way view, see the three-way comparison

One major concern with compounded tirzepatide is the risk of dosing errors
Weight loss varies by medical history, medication, dose, nutrition, activity, adherence, and side effects

A 2021 study published in the New England Journal of Medicine found that individuals who took semaglutide lost an average of 14.9% of their total body weight over the course of one year

For more on general peptide fridge storage timelines , the dedicated guide provides additional context
